BMC pulmonary medicine · 2026
Association of CYFRA 21-1 with quantitative CT-defined fibrotic progression in idiopathic pulmonary fibrosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Ji-Yeon, Lee Hyun-Kyung, Lee Hongyeul, Lee Ho Young, Hong SungMin, Bang Yumi
Аннотация
BACKGROUND AND OBJECTIVE: Although cytokeratin-19 fragment CYFRA 21 - 1 is a potential biomarker for idiopathic pulmonary fibrosis (IPF), its relationship to imaging-based structural progression remains unclear. We evaluated whether baseline CYFRA 21 - 1 is associated with fibrotic progression measured via quantitative computed tomography (QCT) and compared these associations with Krebs von den Lungen-6 (KL-6), including longitudinal relationships between changes in serum biomarker levels and QCT measures.
METHODS: We retrospectively analyzed 95 patients with IPF who underwent volumetric chest CT, serum biomarker analysis including CYFRA 21 - 1 and KL-6, and pulmonary function tests at baseline and approximately 1 year. QCT measurements, including fibrosis, ground-glass opacity (GGO)-reticulation extent, and total interstitial lung disease (ILD) extent, were measured using deep learning-based software.
RESULTS: Baseline CYFRA 21 - 1 was associated with QCT-defined fibrotic progression (odds ratio per 1 ng/mL increase, 1.347; 95% confidence interval [CI], 1.007-1.801). Baseline KL-6 was also associated with fibrotic progression (odds ratio per 100 U/mL increase, 1.085; 95% CI, 1.011-1.164), although the strength of association was lower. Longitudinal increases in CYFRA 21 - 1 were associated with progression of QCT-defined fibrosis (β = 0.943; 95% CI, 0.287-1.600), whereas changes in KL-6 were more closely associated with QCT-derived GGO-reticulation extent (β = 0.429; 95% CI, 0.179-0.680). Neither biomarker was associated with pulmonary function-based progression.
CONCLUSIONS: CYFRA 21 - 1 was associated with QCT-defined fibrotic progression in IPF, whereas KL-6 showed stronger associations with GGO-reticulation extent and total ILD extent on CT. These findings suggest complementary imaging-based association patterns of the two serum biomarkers.
METHODS: We retrospectively analyzed 95 patients with IPF who underwent volumetric chest CT, serum biomarker analysis including CYFRA 21 - 1 and KL-6, and pulmonary function tests at baseline and approximately 1 year. QCT measurements, including fibrosis, ground-glass opacity (GGO)-reticulation extent, and total interstitial lung disease (ILD) extent, were measured using deep learning-based software.
RESULTS: Baseline CYFRA 21 - 1 was associated with QCT-defined fibrotic progression (odds ratio per 1 ng/mL increase, 1.347; 95% confidence interval [CI], 1.007-1.801). Baseline KL-6 was also associated with fibrotic progression (odds ratio per 100 U/mL increase, 1.085; 95% CI, 1.011-1.164), although the strength of association was lower. Longitudinal increases in CYFRA 21 - 1 were associated with progression of QCT-defined fibrosis (β = 0.943; 95% CI, 0.287-1.600), whereas changes in KL-6 were more closely associated with QCT-derived GGO-reticulation extent (β = 0.429; 95% CI, 0.179-0.680). Neither biomarker was associated with pulmonary function-based progression.
CONCLUSIONS: CYFRA 21 - 1 was associated with QCT-defined fibrotic progression in IPF, whereas KL-6 showed stronger associations with GGO-reticulation extent and total ILD extent on CT. These findings suggest complementary imaging-based association patterns of the two serum biomarkers.